ATAI vs. RANI, AVIR, AQST, URGN, MREO, VTYX, SBTX, PGEN, XOMA, and TERN
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Rani Therapeutics (RANI), Atea Pharmaceuticals (AVIR), Aquestive Therapeutics (AQST), UroGen Pharma (URGN), Mereo BioPharma Group (MREO), Ventyx Biosciences (VTYX), Silverback Therapeutics (SBTX), Precigen (PGEN), XOMA (XOMA), and Terns Pharmaceuticals (TERN). These companies are all part of the "medical" sector.
Rani Therapeutics (NASDAQ:RANI) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Rani Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 80.53%. Atai Life Sciences has a consensus price target of $10.50, indicating a potential upside of 412.20%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Rani Therapeutics.
Rani Therapeutics has a net margin of 0.00% compared to Rani Therapeutics' net margin of -12,810.51%. Rani Therapeutics' return on equity of -45.08% beat Atai Life Sciences' return on equity.
Atai Life Sciences received 304 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rani Therapeutics an outperform vote while only 65.92% of users gave Atai Life Sciences an outperform vote.
Rani Therapeutics has higher revenue and earnings than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rani Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
In the previous week, Atai Life Sciences had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Atai Life Sciences and 0 mentions for Rani Therapeutics. Atai Life Sciences' average media sentiment score of 0.80 beat Rani Therapeutics' score of 0.19 indicating that Rani Therapeutics is being referred to more favorably in the media.
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 50.0% of Rani Therapeutics shares are owned by company insiders. Comparatively, 30.0% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Rani Therapeutics beats Atai Life Sciences on 9 of the 17 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
